Fragmin Patient Assistance - Rx Outreach

Phone: 1-877-318-9557

Fax: 1-888-430-9818

Monday - Friday 7:00 AM to 5:30 PM CST


Coverage Policy

The information displayed below pertains specifically to the Hospital Outpatient setting of care. For information tailored to the Physician Office setting or Pharmacy setting, please select the appropriate tab to the left or right. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. See below

Medicare

In general, Medicare considers subcutaneous injectable medications to be self-administered and, therefore, covered under Part D.  However, Medicare covers FRAGMIN® under Part B when administered under a physician’s supervision and under Part D when dispensed for self-administration by a patient or caregiver.  When provided as a Part B benefit, claims for FRAGMIN® are billed to contractors such as Fiscal Intermediaries (hospital outpatient setting), carriers (physician office setting) or the new Part A/B Medicare Administrative Contractors (MACs).  Part D benefit claims for FRAGMIN® are billed to Part D plan sponsors.  Providers should ensure that they are adhering to appropriate local contractor or Part D plan sponsor claim filing requirements when submitting claims for FRAGMIN®.

More information about Medicare Part B

More information about Medicare Part D

Part B vs. Part D

Payor Reimbursement1

FRAGMIN® is not eligible for separate payment under the Medicare Hospital Outpatient Prospective Payment System (OPPS).  Rather, payment for FRAGMIN® is bundled into the payment for the outpatient visit. 

Administration Services2

Drug administration Current Procedural Terminology (CPT) codes are assigned to Ambulatory Payment Classification (APC)s according to their clinical and resource requirements.  Several drug administration codes may map to a single APC.  APCs for drug administration services are updated yearly by CMS. 


For more information on Medicare reimbursement for FRAGMIN®, contact your health plan.

1. Federal Register Vol. 76, No. 230. November 30, 2011. Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment; Ambulatory Surgical Center Payment; Hospital Value-Based Purchasing Program; Physician Self- Referral; and Patient Notification Requirements in Provider Agreements. http://www.cms.gov/HospitalOutpatientPPS/HORD/list.asp#TopOfPage. Accessed November 30, 2011.

2. Medicare Claims Processing Manual Chapter 4, Section 10.2 APC Payment Groups, and Section 230.2.C Payments For Drug Administration Services. Information available on http://www.cms.gov/Manuals/IOM/itemdetail.asp?filterType=none&filterByDID=-99&sortByDID=1&sortOrder=ascending&itemID=CMS018912&intNumPerPage=10. Accessed February 16, 2011.

Indications

FRAGMIN® is a low molecular weight heparin (LMWH) indicated for:

Limitations of Use

Important Safety Information

WARNING: SPINAL/EPIDURAL HEMATOMA

Epidural or spinal hematomas may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

  • Use of indwelling epidural catheters
  • Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
  • A history of traumatic or repeated epidural or spinal punctures
  • A history of spinal deformity or spinal surgery Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see Warnings and Precautions and Drug Interactions].

For more information about FRAGMIN, please see Full Product Information.



Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries.

FRAGMIN® is a registered trademark of Pfizer Heal AB and is licensed to Eisai Inc.

Distributed and marketed by Eisai Inc. CORP74CR8 ©2012 Eisai Inc. All rights reserved.

This site was last modified on : April 2, 2012 at 11:40am ET